06.01.2015 Views

2011 ASH Program Book - American Society of Hypertension

2011 ASH Program Book - American Society of Hypertension

2011 ASH Program Book - American Society of Hypertension

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>2011</strong> <strong>ASH</strong> Exhibitors continued<br />

AtCor Medical, Inc. (USA)<br />

Contact: Beth Boyer<br />

One Pierce Place, Suite 225W<br />

Itasca, IL 60143<br />

Phone: 630-228-8871<br />

Fax: 630-228-8872<br />

Email: info@atcormedical.com<br />

Website: www.atcormedical.com<br />

Booth Number: 1106<br />

AtCor Medical developed and markets SphygmoCor® systems,<br />

the global gold standard in noninvasive assessment <strong>of</strong> central<br />

blood pressure and arterial stiffness. Featured in over 600<br />

published studies, SphygmoCor systems are used worldwide in<br />

leading medical centers, physicians’ <strong>of</strong>fices, in research and in<br />

pharmaceutical clinical trials.<br />

Daiichi Sankyo, Inc.<br />

Contact: Ann Marie Bermudez<br />

2 Hilton Court<br />

Parsippany, NJ 07054<br />

Phone: 973-944-2600<br />

Fax: 973-944-2891<br />

Email: abermudez@dsi.com<br />

Website: www.dsi.com<br />

Booth Number: 1200<br />

Daiichi Sankyo, Inc. (DSI), headquartered in Parsippany, NJ,<br />

is the U. S. subsidiary <strong>of</strong> Daiichi Sankyo Co., Ltd., a global<br />

pharmaceutical company. DSI was formed in 2006 from the<br />

integration <strong>of</strong> two leading pharmaceutical companies, Sankyo<br />

Pharma, Inc. and Daiichi Pharmaceutical Corporation.<br />

Its team <strong>of</strong> nearly 3,000 U.S. employees is dedicated to the<br />

creation and supply <strong>of</strong> innovative pharmaceutical products to<br />

address the diversified, unmet medical needs <strong>of</strong> patients. DSI<br />

concentrates in the therapy areas <strong>of</strong> hypertension, thrombosis,<br />

dyslipidemia, diabetes and acute coronary syndrome. Clinical<br />

development and regulatory activities are headquartered at<br />

Daiichi Sankyo Pharma Development in Edison, NJ. Visit<br />

www.dsi.com.<br />

160

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!